NR ABPN
AU Brandel,J.P.; Peoc'h,K.; Beaudry,P.; Welaratne,A.; Bottos,C.; Agid,Y.; Laplanche,J.L.
TI 14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients
QU Annals of Neurology 2001 Feb; 49(2): 257-60
PT journal article
AB The usefulness of the detection of 14-3-3 protein in the cerebrospinal fluid (CSF) in the diagnosis of Creutzfeldt-Jakob disease transmitted from human growth hormone was evaluated in 20 French patients. The 14-3-3 protein was rarely detectable within the first 3 months of the disease but always positive after 7 months associated with the aggravation of the disease and the occurrence of dementia. 14-3-3 detection was not predictive of the survival time of the patients. The genotype at PRNP codon 129 could influence the timing of appearance of the 14-3-3 protein in the CSF.
MH Creutzfeldt-Jakob Syndrome/*cerebrospinal fluid/drug therapy; Female; Growth Hormone/*therapeutic use; Human; Male; Tyrosine 3-Monooxygenase/*cerebrospinal fluid
AD Centre National de Reference de la MCJ iatrogene, H pital de la Salpetriere, INSERM U360, Paris, France.
SP englisch
PO USA